Standards & Certification
US FDA Compliance for Indian Food & Pharma Exporters
Facility registration, Prior Notice, FSMA, FSVP, import alerts, DWPE, labeling requirements, ANDA filing, and cGMP inspections.
By Aaryan Kakani · · 13 min read
Key takeaways
India exports over $4 billion worth of food products and more than $8 billion in pharmaceutical products to the United States every year. The US Food and Drug Administration (FDA) regulates both categories with a level of scrutiny that surprises many first-time exporters. Unlike most Indian regulatory bodies, the FDA operates on a "guilty until proven innocent" model for imports. Your product can be detained and refused entry based on an automated screening flag, without any physical examination.
For Indian exporters, FDA compliance is not a one-time certification. It is a continuous obligation that spans registration, shipment-level filings, facility inspections, product labeling, and post-market surveillance. This guide covers every major compliance area for both food and pharmaceutical exports to the US. If you are looking for a broader overview of exporting to the United States, see our complete guide to exporting to the USA.
FDA Food Facility Registration
Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (the "Bioterrorism Act"), every foreign facility that manufactures, processes, packs, or holds food intended for US consumption must register with the FDA. This registration is mandatory before you can ship a single consignment to the United States.
Registration is done through the FDA's Unified Registration and Listing System (FURLS) at no cost. You will need to provide details about your facility, the food categories you handle, and critically, designate a US Agent. A person or company physically located in the United States who will serve as the FDA's point of contact with your facility. The US Agent must be available 24/7 and is responsible for receiving and responding to FDA communications on your behalf.
Registration checklist
- Register your facility on the FDA FURLS portal before your first shipment. Keep your FDA registration number (the 11-digit UFI) accessible for all shipment documentation.
- Appoint a reliable US Agent. Many Indian exporters use third-party US Agent services. Verify that your agent actually answers FDA calls and responds to emails promptly.
- Set a calendar reminder for October 1 of every even-numbered year to renew your registration. Do it on Day 1 of the window, not Day 90.
- If your facility address, ownership, or food categories change, update the registration within 60 days. Discrepancies between your registration and your actual operations are a red flag during FDA inspections.
Prior Notice Requirement
Every shipment of food to the United States requires a Prior Notice (PN) filing with the FDA before the goods arrive. This is a shipment-level requirement. Even if your facility is registered, each individual consignment needs its own PN filing. The purpose is to give the FDA advance information so it can target high-risk shipments for inspection.
The filing window depends on the mode of transport. Prior Notice can be filed no more than 15 days before the anticipated arrival date for all modes, but the minimum lead time varies:
| Mode of Transport | Minimum Filing Time Before Arrival | Maximum Filing Time |
|---|---|---|
| Ocean freight | 8 hours | 15 days |
| Air freight | 4 hours | 15 days |
| Road (via Canada/Mexico) | 2 hours | 15 days |
| Rail | 4 hours | 15 days |
Prior Notice is filed through the FDA's Prior Notice System Interface (PNSI) or through the US Customs and Border Protection's (CBP) Automated Broker Interface (ABI). Most Indian exporters rely on their US customs broker to file PN on their behalf, but it remains your responsibility to ensure the information is accurate and filed on time.
FSMA: Food Safety Modernization Act
The Food Safety Modernization Act (FSMA), signed into law in 2011, is the most significant overhaul of US food safety regulation in over 70 years. FSMA shifted the FDA's approach from reacting to foodborne illness outbreaks to preventing them. For Indian food exporters, two FSMA provisions are particularly important: the Foreign Supplier Verification Program (FSVP) and the Preventive Controls rule.
Foreign Supplier Verification Program (FSVP)
FSVP places the compliance burden on the US importer , not the Indian exporter. Under FSVP, every US importer must verify that the food they import has been produced in compliance with US safety standards. In practice, this means your US buyer will require you to provide:
- Hazard analysis documentation for each product you export
- Evidence of preventive controls. Your HACCP plan, SOPs, environmental monitoring records, and allergen control procedures
- Third-party audit reports from FDA-recognised accreditation bodies (especially if your product category is high-risk)
- Supplier qualification records, including your facility's compliance history and any past FDA observations
If your US importer cannot verify that your facility meets FSVP requirements, they are legally prohibited from importing your products. Many Indian exporters lose US buyers not because of price or quality, but because they cannot produce the documentation FSVP demands.
PCQI: Preventive Controls Qualified Individual
Under FSMA's Preventive Controls for Human Food rule, every food facility must have a Preventive Controls Qualified Individual (PCQI) who has completed FDA-recognised training in food safety preventive controls. The PCQI is responsible for developing the facility's food safety plan, validating preventive controls, and reviewing records.
While the PCQI requirement technically applies to US-based facilities, having a PCQI-trained professional at your Indian facility has become a de facto requirement. US importers under FSVP routinely ask Indian suppliers whether they have PCQI training, and many will not onboard a new supplier without it. The FDA's Food Safety Preventive Controls Alliance (FSPCA) offers standardised training that is recognised globally.
FDA Import Alerts on Indian Products
Import Alerts are the FDA's enforcement tool for flagging products, firms, or entire countries whose shipments have a history of violations. When your firm or product is listed on an Import Alert, your shipments are automatically detained at US ports. Often without any physical examination (known as DWPE, covered in the next section).
India consistently has one of the highest numbers of import alert listings among all countries. The following three import alerts affect Indian exporters most frequently:
| Import Alert | Products Affected | Common Violations |
|---|---|---|
| 99-19 | Spices, seasonings, and seeds | Insect filth, rodent contamination, Salmonella, mould |
| 16-124 | Seafood and fishery products | Decomposition, Salmonella, Listeria, veterinary drug residues, filthy conditions |
| 99-32 | Dietary supplements | Unapproved new drug claims, undeclared ingredients, cGMP violations, adulteration |
Beyond these three, Indian products also appear on import alerts for pesticide residues in rice and tea (Import Alert 99-08), unapproved colour additives in confectionery and sweets (Import Alert 45-02), and unsafe food additives. The FDA maintains and updates these lists publicly, and Indian exporters should check the Import Alert database regularly to ensure they are not listed.
DWPE: Detention Without Physical Examination
Detention Without Physical Examination (DWPE) is the mechanism behind import alerts. When the FDA places your firm or product on DWPE, it means your shipments will be automatically detained at the US port of entry based solely on the shipping documents. No one needs to open the container or test the product. The detention is triggered by an automated match against the FDA's Import Alert system.
Once detained, the burden of proof shifts entirely to the exporter. You must demonstrate that the specific shipment meets FDA requirements, typically by providing independent laboratory test results from an FDA-recognised lab. Even with clean test results, the review process can take weeks, during which your goods sit at the port accumulating demurrage and storage charges.
How to Get Off the DWPE / Import Alert List
Getting removed from an Import Alert is possible but requires sustained effort. The FDA's general requirements for removal include:
Steps to get off the DWPE list
- Identify the specific violation. Review your FDA refusal letter or the Import Alert listing to understand exactly why you were listed. Filth, Salmonella, labeling, or another violation.
- Implement corrective actions. Develop and document a Corrective Action Preventive Action (CAPA) plan addressing the root cause. This must include facility upgrades, process changes, and enhanced testing protocols.
- Build a track record of clean shipments. You typically need to demonstrate five consecutive violation-free shipments with independent lab test results from an FDA-recognised laboratory accompanying each one.
- Request an FDA facility inspection. For serious violations, the FDA may require a successful facility inspection before removal. This means an FDA investigator will visit your Indian facility.
- Submit a formal removal request. File a petition to the FDA Division of Import Operations and Policy with all supporting documentation. Include your CAPA plan, lab results, and evidence of sustained compliance.
FDA Inspections of Indian Facilities
The FDA inspects foreign food and pharmaceutical facilities as part of its enforcement programme. India is one of the most frequently inspected countries due to the volume of exports and the history of violations. The FDA's India office, established in New Delhi and Mumbai, coordinates these inspections.
FDA inspections of Indian facilities can be classified into three types:
| Inspection Type | Trigger | Typical Duration |
|---|---|---|
| Routine / Surveillance | Scheduled based on facility risk ranking and time since last inspection | 3-7 days |
| Pre-Approval (PAI) | Before FDA approval of an ANDA or NDA (pharma) or a new food facility registration | 5-10 days |
| For-Cause / Compliance | Triggered by an adverse event, consumer complaint, import refusal, or failed sample testing | 5-14 days |
After an inspection, the FDA investigator issues one of three outcomes: No Action Indicated (NAI) (no significant violations found; Voluntary Action Indicated (VAI)) violations found but not severe enough for enforcement; or Official Action Indicated (OAI). Significant violations that trigger regulatory action such as warning letters, import alerts, or consent decrees.
If violations are found, the investigator issues a Form FDA 483 listing the observations. You have 15 business days to respond in writing with your corrective action plan. The quality and specificity of your 483 response is critical. A vague or incomplete response will escalate the matter to a warning letter.
Labeling Requirements for the US Market
FDA labeling requirements for food products are extremely specific and differ significantly from Indian (FSSAI) labeling norms. Products with non-compliant labels are refused entry at US ports. Labeling violations are one of the top three reasons for FDA import refusals of Indian food products.
Key FDA labeling requirements include:
Mandatory label elements (21 CFR Part 101)
- Statement of identity. The common name of the food in English, displayed prominently on the principal display panel (PDP)
- Net quantity. In both metric and US customary units (e.g., "200g (7 oz)"), placed in the lower 30% of the PDP
- Nutrition Facts panel. In the specific FDA format with serving sizes in US household measures, per-serving and per-container values, and all mandatory nutrients listed in the prescribed order
- Ingredient list. In descending order of predominance by weight, using FDA-standard ingredient names (not FSSAI names, which may differ)
- Allergen declaration. The eight major allergens (now nine, with sesame added in 2023) must be declared in plain English using a "Contains" statement or in parentheses within the ingredient list
- Name and address of manufacturer, packer, or distributor. Must include the city, state, and ZIP code of the US-based responsible party
- Country of origin. "Product of India" must be clearly displayed
Common Reasons for FDA Refusal of Indian Products
The FDA publishes import refusal data publicly. Analysing the refusal reports for Indian products reveals consistent patterns. Understanding these patterns helps you avoid the most common pitfalls:
| Refusal Reason | FDA Violation Code | Products Most Affected |
|---|---|---|
| Filth (insect, rodent, mould) | Adulteration 402(a)(3) | Spices, rice, dried vegetables |
| Salmonella contamination | Adulteration 402(a)(1) | Spices, sesame seeds, seafood |
| Labeling violations | Misbranding 403(i), 403(q) | Packaged snacks, ready-to-eat meals, sweets |
| Unapproved colour additives | Adulteration 402(c) | Confectionery, sweets, sauces |
| Pesticide residues | Adulteration 402(a)(2)(B) | Rice, tea, dried fruits |
| No facility registration / lapsed registration | Section 801(l) | All food categories |
| Missing or incomplete Prior Notice | Section 801(m) | All food categories |
Pharma Exports: ANDA, cGMP, and Warning Letters
India is the world's largest supplier of generic drugs to the United States, with Indian pharmaceutical companies accounting for nearly 40% of all generic drug approvals by the FDA. This scale of exports comes with intense regulatory scrutiny.
ANDA Filing (Abbreviated New Drug Application)
To sell a generic drug in the US market, an Indian pharma company must file an ANDA with the FDA. The ANDA must demonstrate that the generic product is bioequivalent to the reference listed drug (RLD), is manufactured in a facility that meets cGMP standards, and that the labeling is consistent with FDA requirements. The ANDA review process typically takes 10-15 months for a standard review and 8-10 months for a priority review.
Before the FDA approves an ANDA, it conducts a Pre-Approval Inspection (PAI) of the manufacturing facility. This is where many Indian applications stall. The facility must demonstrate full compliance with current Good Manufacturing Practices (cGMP) as defined in 21 CFR Parts 210 and 211.
cGMP Requirements (21 CFR Parts 210 & 211)
Current Good Manufacturing Practices for pharmaceuticals cover every aspect of drug manufacturing. From personnel qualifications and building design to laboratory controls and record-keeping. The areas where Indian pharma facilities most frequently fail FDA inspections include:
- Data integrity. By far the most common violation. Includes manipulation of test results, deletion of out-of-specification (OOS) data, backdating of records, and using "trial" injections before official testing
- Laboratory controls. Inadequate investigation of OOS results, failure to validate analytical methods, and insufficient stability testing
- Equipment maintenance and cleaning. Inadequate cleaning validation between product changeovers, leading to cross-contamination risks
- Process validation. Insufficient data to demonstrate that the manufacturing process consistently produces product meeting its specifications
- Quality unit oversight. The quality unit not exercising sufficient authority to reject batches, investigate complaints, or halt production when necessary
FDA Warning Letters to Indian Pharma Companies
The FDA has issued warning letters to some of India's largest pharmaceutical companies, including Sun Pharma, Dr. Reddy's, Aurobindo, Lupin, and Wockhardt. Warning letters are published on the FDA website and are publicly searchable. A warning letter signals that the FDA found significant cGMP violations during an inspection and that the company has failed to take adequate corrective action in response to Form 483 observations.
The consequences of a warning letter are severe: the FDA may withhold approval of pending ANDAs from that facility, issue an import alert placing all products from the facility on DWPE, and require a successful re-inspection before any new approvals are granted. For publicly listed pharma companies, a warning letter also causes immediate stock price damage and reputational harm.
Frequently Asked Questions
Do Indian food exporters need to register with the US FDA?
Yes. Under the Bioterrorism Act and FSMA, every foreign facility that manufactures, processes, packs, or holds food for US consumption must register with the FDA through the FURLS portal. Registration is free, requires a designated US Agent, and must be renewed biennially during October. December of every even-numbered year. Without an active registration, your products will be refused entry at US ports.
What is Prior Notice and how far in advance must it be filed?
Prior Notice is a mandatory filing submitted to the FDA before any food shipment arrives in the US. For ocean freight, file at least 8 hours before arrival; for air freight, at least 4 hours; for road, at least 2 hours. All modes allow filing up to 15 days in advance. PN is filed through the FDA's PNSI or through CBP's ABI. No PN means no entry. The shipment will be refused.
What is Import Alert 99-19 and how does it affect Indian spice exporters?
Import Alert 99-19 authorises DWPE (automatic detention) of spices, seasonings, and seeds due to filth contamination. Hundreds of Indian firms are listed. Products from listed firms are detained at US ports without physical examination. Removal requires five consecutive clean shipments with independent lab results, a corrective action plan, and potentially an FDA facility inspection.
What are the FDA requirements for Indian pharmaceutical exporters to the US?
Indian pharma companies must file an ANDA for each generic drug, pass a Pre-Approval Inspection, and maintain continuous cGMP compliance under 21 CFR Parts 210 and 211. The FDA inspects Indian pharma facilities regularly and has issued warning letters to several major Indian companies. Data integrity, laboratory controls, equipment cleaning, and process validation are the most common areas of non-compliance. A warning letter can freeze all pending ANDAs from the affected facility.
Update history
- First published.